Overview

A class action lawsuit has been filed against Intellia Therapeutics, Inc. (“Intellia” or the “Company”) and certain of the Company’s former senior executive officers alleging violations of the federal securities laws.  The Company’s common stock traded on the NASDAQ Stock Market under the symbol “NTLA.”

The Intellia class action lawsuit was brought on behalf of all persons and entities who purchased or otherwise acquired Intellia securities between July 30, 2024, to January 8, 2025, both dates inclusive (the “Class Period”).

Intellia describes itself as a leading clinical-stage gene editing company, focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.  The Company advances its platform’s modular solutions and research efforts on genome editing technologies as well as delivery and cell engineering capabilities to generate additional development candidates.

On July 30, 2024, Intellia announced the authorization of its Clinical Trial Application (CTA) by the United Kingdom’s Medicine and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 study evaluating NTLA-3001 for the treatment of alpha1 antitrypsin deficiency (AATD)-associated lung disease.

The Elastic class action lawsuit alleges that Defendants created the false impression that they possessed reliable information pertaining to the viability of NTLA-3001’s development and eventual marketing, if approved.  In truth, Intellia’s optimistic reports of timelines, including dosing and future studies of the drug, fell short of reality; the NTLA program was not viable or sustainable for the Company because viral-based editing programs remained expensive and inefficient in comparison to then-existing nonviral delivery methods.  Intellia was not equipped to timely dose patients with NTLA-3001, maintain the drug’s research and development, or even to maintain its full staff in light of the existing scientific landscape surrounding viral-based editing drugs.  In fact, even if NTLA-3001 proved successful, the use of viral-based editing drugs is costly, inefficient, and a poor mitigator of adverse effects in patients.

Investors and analysts reacted immediately to Intellia’s revelation.  The price of Intellia’s common stock declined dramatically.  From a closing market price of $12.02 per share on January 8, 2025, Intellia’s stock price fell to $10.20 per share on January 10, 2025, a decline of about 15% in the span of just a single day.

*          *          *

If you purchased or otherwise acquired Intellia securities between July 30, 2024 to January 8, 2025, both dates inclusive, and you wish to serve as lead plaintiff in this lawsuit, we encourage you to submit your information to DiCello Levitt LLP via the form on this page. 

You can also contact DiCello Levitt partner Brian O’Mara by calling (888) 287-9005 or at [email protected]. 

The deadline to apply to the Court to serve as lead plaintiff in the Intellia class action lawsuit is April 14, 2025.